The actual benefit provided by LOJUXTA in combination with other lipid lowering medicines is substantial in adult patients with homozygous familial hypercholesterolaemia (HoFH) uncontrolled by these lipid-lowering treatments used at maximum doses, whether or not combined with apheresis.
Clinical Added Value
minor
The addition of LOJUXTA to an optimal lipid-lowering therapy, used at maximum doses, whether or not combined with apheres is, in adult patients with uncontrolled homozygous familial hypercholesterolaemia (HoFH), provides a minor improvement in actual benefit (IABIV).
Listen
